Eyenovia Showcases Microdose Array Print (MAP™) Technology at CES 2023 in Las Vegas
31 janv. 2023 09h00 HE
|
Eyenovia
LAS VEGAS, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its...
Eyenovia Aims to Revolutionize Ophthalmology Devices With Microdose Array Print (MAP) Technology
22 déc. 2022 09h01 HE
|
Eyenovia
NEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE) -- While medical devices have seen incredible advancements over the last 100 years, ocular drug delivery systems have seen minimal progress; the standard eye...
Investigational Optejet® Microdose Dispenser from Eyenovia Shows Promise in Improving Treatment for Myopia, Presbyopia and Patients Getting Eye Exams
17 oct. 2022 09h01 HE
|
Eyenovia
NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Two recent studies show that the novel Optejet® dispenser from Eyenovia, Inc., an ophthalmic pharmaceutical technology company, may be a more...
Eyenovia Chairman Dr. Sean Ianchulev: The Making Of An iDoctor - Immigrant, Innovator, Inventor
21 sept. 2022 10h01 HE
|
Eyenovia
NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Before founding Eyenovia, Dr. Sean Ianchulev had established himself as a pioneer and innovator in the field of ophthalmology. Inspired by his mother, a...
Eyenovia's Novel Optejet® Dispenser Puts People's Eyes First
30 août 2022 09h01 HE
|
Eyenovia
NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, brings...
Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating Possible Securities Fraud Violations by Certain Officers and Directors of Menlo Therapeutics, Hill International, and Eyenovia on Behalf of Stockholders and Encourages Investors to Contact the Firm
24 sept. 2018 19h22 HE
|
Bragar Eagel & Squire
NEW YORK, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Menlo Therapeutics Inc., Hill...
Bragar Eagel & Squire, P.C. is Investigating Eyenovia, Inc. (EYEN) on Behalf of Stockholders and Encourages Investors to Contact the Firm
17 août 2018 15h39 HE
|
Bragar Eagel & Squire
NEW YORK, Aug. 17, 2018 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against Eyenovia, Inc. (NASDAQ: EYEN). Our investigation concerns whether Eyenovia has...
Eyenovia, Inc. announces publication of Phase II study results demonstrating benefits of micro-formulation over conventional eyedroppers and addition of Scientific Advisory Board members
28 nov. 2016 15h46 HE
|
Eyenovia, Inc
Eyenovia’s study shows that conventional ophthalmic eye drops significantly overdose the eye and that equivalent, or greater, pharmacodynamic effect can be achieved with 80% less ocular exposure...